Dar es Salaam — The President of Zanzibar, Dr Hussein Mwinyi, has ordered state institutions to incorporate rare disease treatment in the health policy so that children facing such health issues can receive specialised care, particularly oxygen. Dr Mwinyi made the statement on Tuesday evening when he spoke to delegates...
Latest News
The ground wobbles a little when your newborn is diagnosed with a rare disease. It threatens to swallow you whole when you learn a NICU attending has to distribute two stapled pages to each of his staff summarizing your daughter’s condition. They had never before treated a child with Hilde’s diagnosis, let alone...
BALTIMORE – MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders...
BALTIMORE – Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence. MYMD-1 is...
MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a G-protein-coupled receptor 17 (GPR17) antagonist, for the...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101) in Nature Medicine. The published article, entitled, “Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company”), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101) in Nature Medicine. The published article, entitled, “Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2...
NEW YORK, NY — Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on developing treatments for neurodegenerative diseases, today announced its participation in the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting where clinical trial data from its...
NEW YORK, NY — Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) Designation to the Company’s lead gene therapy product candidate, rAAV-Olig001-ASPA for the treatment of...